The receptor for advanced glycation end products impairs collateral formation in both diabetic and non-diabetic mice

Diabetics often have poor perfusion in their limbs as a result of peripheral artery disease and an impaired ability to generate collateral vessels. The receptor for advanced glycation end products (RAGE) is one protein that is thought to play a detrimental role in collateral development in diabetics due increased levels of advanced glycation end products (AGE), one of its ligands, in diabetes. Thus the aim of this study was to investigate the role of RAGE in both diabetic and non-diabetic settings in a model of collateral formation in mice. Streptozotocin was used to induce diabetes in both wild type and RAGE knockout mice. Increased levels of the AGE, N(ε)-(carboxymethyl) lysine (CML), were confirmed via an ELISA. A hindlimb ischemia model, in which the femoral artery is ligated, was used to drive collateral growth and reperfusion was assessed using laser Doppler perfusion imaging and histological analysis of vessels in the muscle. Both of these measurements showed impaired collateral growth in diabetic compared to wildtype mice as well as improved collateral growth in both diabetic and non-diabetic RAGE knockout mice when compared their wildtype counterparts. Distance on a freely accessed running wheel, used as a measure of perfusion recovery, showed that wildtype diabetic mice had functionally impaired recovery compared to their wildtype counterparts. Immunohistochemistry and immunoblotting showed that HMGB-1 (high mobility group box 1), another RAGE ligand, was increased in the ischemic leg compared to the non-ischemic leg in all mice. This increase in HMGB-1 may explain improvement in animals lacking RAGE and its subsequent signaling. In conclusion, this study shows that RAGE impairs collateral growth in a diabetic setting and also in a non-diabetic setting. This demonstrates the importance of RAGE and alternate RAGE ligands in the setting of collateral vessel growth.